Insights
Newsletters
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Newsletters
The Entrepreneurs Report – Q1 2026
Wilson Sonsini is pleased to present the Q1 2026 edition of The Entrepreneurs Report. We’ve compiled a range of data on venture, convertible note, and SAFE financing transactions in which the firm was involved during the first quarter, with the objective of identifying relevant trends in activity and valuation levels for the U.S. venture capital industry in general.
Newsletters
Wilson Sonsini Global Cartel Law Quarterly Q4 2025/Q1 2026
The firm is pleased to distribute the Wilson Sonsini Global Cartel Law Quarterly Q4 2025/Q1 2026, which provides a summary of key cartel enforcement trends across the U.S., Europe, and beyond. A “cartel” under competition law is typically reserved for agreements between competitors to restrict competition, such as price-fixing, bid-rigging, and market allocations.
All Results
Client Highlights
6.16.26
Firm Advises 4E Therapeutics on Acquisition by Eli Lilly
On June 16, 2026, 4E Therapeutics, an Austin-based neuroscience company developing next-generation treatments for chronic pain, announced that it has been acquired by Eli Lilly and Company. Wilson Sonsini Goodrich & Rosati advised 4E Therapeutics on the transaction.
Alerts
6.15.26
Delaware Enacts Uniform Assignment for the Benefit of Creditors Law
On June 10, 2026, Delaware joined four other states and enacted a version of the Uniform Assignment for the Benefit of Creditors Act (the Act). The Act constitutes a significant change to Delaware’s prior statute, first enacted in 1875, and modernizes and streamlines Delaware’s assignment for the benefit of creditors process.1
Bylined Articles
6.15.26
Law360 Article: “7 Key Questions About SEC’s Faster Tender Offer Path”
Wilson Sonsini attorneys Rob Ishii, Doug Schnell, Remi Korenblit, Tamara Brightwell, and Michael Anthony authored a recent Law360 article titled "7 Key Questions About SEC’s Faster Tender Offer Path." The piece examines the recent order issued by the SEC to shorten the minimum offering period on certain equity tender offers. The authors walk through seven key questions covering eligibility requirements, timeline implications, private company applicability, and strategic considerations—noting that while the shortened period offers meaningful efficiency gains, parties must carefully weigh trade-offs, including reduced time for boards to consider topping proposals and potential sequencing issues with go-shop periods.
News Articles
6.15.26
OneJustice Recognizes Wilson Sonsini as a 2026 Champion of Justice
On June 11, 2026, Wilson Sonsini Goodrich & Rosati was recognized by OneJustice as a co-honoree Champion of Justice for the firm’s partnership with Community Legal Services in East Palo Alto (CLSEPA). The Champion of Justice award honors legal aid and pro bono champions for going above and beyond to provide legal services to community members in the greatest need.
Press Releases
6.15.26
Wilson Sonsini Co-Sponsors Third Annual Rome Conference on AI, Ethics, and Governance
PALO ALTO, CA (June 15, 2026)—Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, will co-sponsor the Annual Rome Conference on AI, Ethics, and Governance for the third consecutive year. Taking place on June 18-20, 2026, in Rome, the conference will convene leaders across technology, business, policy, academia, religious, and civil society to examine the far-reaching human, ethical, and institutional implications of artificial intelligence. This year’s program builds on prior years with a heightened emphasis on ethics and governance for AI’s increasingly transformative role in society.
Client Highlights
6.11.26
Wilson Sonsini Advises Adyen on $335 Million Acquisition of Orb
On June 11, 2026, Adyen N.V. (AMS: ADYEN), a global financial technology platform, announced it has entered into a definitive agreement to acquire enterprise billing platform Orb for $335 million. Upon closing, Orb will become an indirect, wholly owned subsidiary managed under an incubator model. The strategic intent is to eventually create a unified infrastructure experience for merchants across billing and payments.
Client Highlights
6.11.26
Wilson Sonsini Advises Beren Therapeutics P.B.C. on $300 Million Financing, Including Equity and Debt and Royalty Facilities
On June 10, 2026, Beren Therapeutics P.B.C., a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, announced it has secured $300 million in combined financing. The financing consists of:
Client Highlights
6.11.26
Wilson Sonsini Advises Maneva on $27 Million Series A
On June 10, 2026, Maneva, the video-to-action AI company building the intelligence layer for modern manufacturing, announced $27 million in Series A funding, accelerating its mission to close the $18 trillion global manufacturing efficiency gap. The Series A round was led by U.S. Venture Partners (USVP), with participation from returning investors Bling Capital and Freestyle Capital, alongside a group of leading angel investors and funds. This fundraise brings Maneva’s total capital raised to $38.4 million. Wilson Sonsini Goodrich & Rosati advised Maneva on the transaction.
The proceeds from the Series A will position Maneva to accelerate on three fronts: deepening its core AI capabilities through continued development of its patent-pending VITA and ALIS agents, expanding its customer base into new geographies and industries, and rolling out its next generation of factory orchestration and AI knowledge agent features.
The Wilson Sonsini team that advised Maneva on the transaction included Rezwan Pavri, Lester Ang, Karin Hjorth, and Keili Prenton.
For more information, please see Maneva’s news release.
The proceeds from the Series A will position Maneva to accelerate on three fronts: deepening its core AI capabilities through continued development of its patent-pending VITA and ALIS agents, expanding its customer base into new geographies and industries, and rolling out its next generation of factory orchestration and AI knowledge agent features.
The Wilson Sonsini team that advised Maneva on the transaction included Rezwan Pavri, Lester Ang, Karin Hjorth, and Keili Prenton.
For more information, please see Maneva’s news release.
Alerts
6.10.26
New York Legislature Passes Ban on Personalized Pricing
Last week, the New York State Legislature passed the One Fair Price Act (S.8623B/A.9349B) (the Act), a bill that prohibits businesses from using personal data—such as purchase history, browsing history, real-time location, income, or inferred household size—to generate individual prices for consumers. While the Act bans so-called “surveillance pricing,” or personalized pricing, companies may still use “dynamic pricing” algorithms, subject to a modified disclosure requirement, so long as the algorithm does not set prices based on consumer personal data. The bill now awaits the signature of Governor Kathy Hochul, who has until December 31, 2026, to act.
Client Highlights
6.10.26
Wilson Sonsini Advises Kiavi on $717 Million Acquisition by Figure
On June 10, 2026, Figure Technology Solutions (Figure), the blockchain-native capital marketplace for the origination, funding, sale, and trading of tokenized assets, announced a definitive agreement to acquire Kiavi, an AI-powered lending platform for residential real estate investors. The transaction includes the purchase of Kiavi’s balance sheet assets by a joint venture between Figure and Sixth Street, a leading global investment firm, who is buying loans off Kiavi’s balance sheet. The total transaction purchase price is $717 million. Wilson Sonsini Goodrich & Rosati is advising Kiavi on the transaction.
Client Highlights
6.10.26
Wilson Sonsini Advises SonoThera on Patent Matters Related to Oversubscribed $125 Million Series B
On June 10, 2026, SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines. Wilson Sonsini Goodrich & Rosati advised SonoThera on patent matters related to the transaction.